Wilburton native serves as scientific adviser to consulting corporation
LYNN, Mass. - Dr. Susan Dallabrida, a native of Wilburton, has joined PHT Consulting Services, located in Boston and Geneva, as a senior scientific adviser.
She is a daughter of Karen and Don Dallabrida, of Wilburton, and a granddaughter of Marion A. Wydra, of Mount Carmel.
PHT Corporation is the leading provider of innovative technology systems used to collect patent-driven edata for clinical research.
Dallabrida provides scientific guidance and analysis, serving as a liaison with PHT clients and internal teams.
Dallabrida has more than 10 years experience as a senior scientist and project director in research and development, clinical trial design and strategy and product development. She has led cross-functional drug discovery and product development teams in such areas as oncology, cardiovascular disease, hemophilia, dermatology, obesity and vascular disorders.
"We're excited that a world class scientist of Susan Dallabrida's caliber chose to join PHT," said Lisa Anne Markel, PHT vice president of technical operations. "She understands all facets of clinical research technology across the spectrum, from design and development to patient usage. Her excellent reputation, insights and accomplishments in science and technology will be a tremendous contribution as we continue driving innovation in clinical research that collects clinical outcome assessments."
Dallabrida has significant regulatory experience in the U.S. and internationally for biologics. She also has a broad background in scientific presentations and writing with 20 publications, 14 grants, three patents, 18 awards, 26 conference presentations and 14 abstracts.
Dallabrida earned a Bachelor of Science in biology and a Bachelor of Arts in chemistry from Bloomsburg University and a Ph.D. in biochemistry and molecular biology from Pennsylvania State University. She conducted her post-doctoral training at Harvard Medical School and then had a translational laboratory at the Harvard Medical School for seven years before moving to biotechnology,